GlassScriptPhysician profile
Clay Andrew Simon
NPI 1083336382
$757.53
in general payments reported to CMS, 2019-2025
11 companies · $548 in 2025
The $548 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.68 · 2024: $194 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $324.92 | 2024-2025 | Evoke |
| Collegium Pharmaceutical, INC. | $117.16 | 2024-2025 | Belbuca |
| Abbott Laboratories | $103.66 | 2025 | Eterna |
| Vertex Pharmaceuticals Incorporated | $58.90 | 2025 | |
| Globus Medical, INC. | $37.35 | 2025 | Senza |
| Abbvie INC. | $28.01 | 2025 | |
| Kyowa Kirin, INC. | $21.25 | 2025 | |
| Spr Therapeutics, INC | $18.72 | 2024 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.21 | 2024 | Relistor |
| Vapotherm INC | $15.68 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.67 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.